Signmod Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.32 M
- Company Age 14 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -60.59%
- Profit Growth -151.13%
- Ebitda 3799.28%
- Net Worth -2.06%
- Total Assets -60.57%
About Signmod Pharmaceuticals
Signmod Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 March 2010 and has a history of 14 years and ten months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.32 M, as per Ministry of Corporate Affairs (MCA) records.
Prabhat Arya, Arvindh Shanmugam, and Rajamohan Poondra serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232TG2010PTC067623
-
Company No.
067623
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
19 Mar 2010
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Signmod Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prabhat Arya
|
Director | 19-Mar-2010 | Current |
|
Arvindh Shanmugam
|
Director | 04-Sep-2018 | Current |
|
Rajamohan Poondra
|
Additional Director | 01-Feb-2021 | Current |
Financial Performance of Signmod Pharmaceuticals.
Signmod Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 60.59% decrease. The company also saw a substantial fall in profitability, with a 151.13% decrease in profit. The company's net worth dipped by a decrease of 2.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Signmod Pharmaceuticals?
In 2018, Signmod Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Smagen Pharma Private LimitedPrabhat Arya is a mutual person
-
Nihita Therapeutics Private Limited
Prabhat Arya is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Signmod Pharmaceuticals?
Unlock and access historical data on people associated with Signmod Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Signmod Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Signmod Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
